Clinical Trial Update: Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies [Phase 3]

View source ↗

Summary

Phase 3 study evaluating a fixed-dose combination of obicetrapib and ezetimibe added to existing lipid-modifying therapy has completed. Results have been posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Dyslipidemia
• Familial Hypercholesterolemia
• Hypercholesterolemia

Drugs mentioned

• EZETIMIBE (EZETIMIBE)
• Obicetrapib (obicetrapib)

Snippet

Sponsor: NewAmsterdam Pharma | Conditions: Dyslipidemias, Hypercholesterolemia | Phase 3 | Status: COMPLETED | Results posted: 2025-10-08